1. INTRODUCTION:

Cancer has been one the global lead health problem, as conventional treatments such as chemotherapy, radiation, and surgical procedures frequently prove inadequate due to their nonspecific mechanisms, significant toxicity, poor solubility of therapeutic agents, and the common emergence of multidrug resistance (MDR). These issues are particularly pronounced in aggressive cancers like glioblastoma, where the results of standard treatments are often unsatisfactory. In an effort to address these challenges, researchers have explored nanotechnology-based strategies—especially dendrimer-based systems. Dendrimers are synthetic macromolecules characterized by a tree-like structure, possessing adjustable surface chemistry and the ability to transport a diverse array of therapeutic agents, whether hydrophilic or hydrophobic. Nevertheless, obstacles such as systemic toxicity and inadequate targeting have prompted the development of hybrid systems¹.

These dendrimer-based hybrid systems take advantage of the unique strengths of each component to boost the overall effectiveness of cancer treatment. For example, they can support dual or combination therapies—like merging photothermal therapy (PTT) with chemotherapy—on a single platform to produce a more powerful, synergistic effect².

Adding biological targeting agents such as folic acid or transferrin helps guide the treatment more directly to cancer cells, which also means there's less risk of harming healthy tissues. Some advanced designs even include imaging elements, allowing doctors to monitor treatment progress in real time—a strategy known as theranostics³.

2. Background: Dendrimer Hybrids in Synergistic Cancer Therapy

2.1 Clinical Challenges in Treating Brain Tumors and Drug Administration:

Brain tumors, particularly glioblastoma multiforme (GBM), are highly aggressive and difficult to treat due to rapid growth, invasiveness, and complex genetics. Despite using surgery, chemotherapy, and radiation, treatment outcomes remain poor. The blood–brain barrier blocks many drugs from reaching the tumor, limiting effective delivery, while tumor heterogeneity and drug resistance further complicate therapy⁴.

Fig 1: Glioblastoma tumor¹⁹

2.2 The Function of Nanomedicine and Dendrimers:

Nanomedicine is transforming cancer treatment by enabling targeted drug delivery, improving solubility of poorly water-soluble drugs, and allowing controlled release for selective action at tumor sites. Among nanocarriers, dendrimers particularly poly(amidoamine) (PAMAM) types stand out for their symmetrical, branched structure, internal cavities for drug encapsulation, and modifiable surfaces. PEGylation, the attachment of polyethylene glycol chains, is a key modification that further enhances their therapeutic potential⁵.

2.3 The Emerging Potential of Dendrimer Hybrids in Synergistic Therapy:

Dendrimer hybrids are emerging as a promising new approach in cancer treatment, combining the unique features of dendrimers with various therapeutic agents or delivery technologies to improve outcomes. These hybrid systems are capable of delivering multiple types of treatment at once such as chemotherapy drugs, gene-silencing molecules like siRNA, or photothermal agents which can work together to create a stronger, more effective therapeutic response. By using this kind of combination therapy, it's often possible to lower the dose of each individual drug, which can help reduce side effects⁶.

3. Evolution of Dendrimer-Based Nanocarriers in Oncology :

3.1. Introduction to Dendrimers in Cancer Therapy:

Dendrimers, first developed in the late 1970s, are synthetic macromolecules with a highly branched, tree-like nanoscale structure. Poly (amidoamine) (PAMAM) dendrimers are the most studied for their uniform architecture, water solubility, and adaptable surfaces, making them ideal carriers for diverse therapeutics. They are now valued for targeted drug delivery, particularly in cancer therapy where precise and efficient delivery is crucial⁷.

Fig 2: Schematic View of G4 Pamam Dendrimer¹⁸

3.2 Limitations of Early-Generation Dendrimers:

Early-generation dendrimers with unmodified, positively charged surfaces showed initial promise but were limited by safety issues, as their strong charge caused cytotoxicity, hemolysis, and immune reactions. They were also rapidly cleared from the bloodstream, reducing effectiveness. These challenges led to structural modifications like PEGylation, acetylation, and ligand conjugation to improve biocompatibility, extend circulation, and enhance drug delivery.

3.3 Progress in Surface Engineering:

To enhance dendrimer biocompatibility and performance, researchers use surface modifications such as attaching polyethylene glycol (PEG), acetyl groups, or targeting ligands. These reduce immune responses, extend circulation time, and improve tumor recognition, making dendrimers safer and more effective by minimizing interactions with healthy tissues and improving function in the body⁸.

3.4 Emergence of Dendrimers Hybrids:

While dendrimers show promise in drug delivery, their limited drug-loading capacity and variable performance in complex tumor environments have prompted the development of hybrids with liposomes, biodegradable polymers, gold or silica nanoparticles, and carbon-based materials. These combinations leverage the strengths of each component, improving drug delivery, stability, and tumor targeting.

3.5 Multifunctional Capabilities of Hybrid Systems:

Dendrimer-based hybrid systems can carry multiple therapeutic agents, holding both hydrophilic and hydrophobic drugs in one structure to improve delivery. Combining dendrimers with liposomes boosts drug-loading and bioavailability, while polymer-based hybrids can be designed to respond to tumor-specific signals like acidic pH or enzymes for precise drug release.

4. Classification of Dendrimer Hybrids:

Dendrimer hybrids are advanced nanocarriers formed by combining dendrimers with other nanomaterials to improve drug delivery. They address limitations of standalone dendrimers, like low drug payload or rapid clearance, by integrating complementary materials. Depending on the co-material and intended use drug delivery, imaging, or combination therapies—they can be classified into several major types⁹.

4.1 Dendrimer–Lipid Hybrids:

Dendrimer–lipid hybrids represent one of the most extensively researched systems within the realm of cancer nanomedicine. These hybrids integrate dendrimers with liposomes or lipid bilayers to enhance drug encapsulation and stability during circulation. This lipid part plays a important role in improving biocompatibility and emulating natural cell membranes, whereas dendrimers contribute to the structural integrity and capacity for drug delivery¹⁰.

4.2 Dendrimer–Polymerd Hybrids:

Dendrimer–polymer hybrids are formed through covalent or non-covalent interactions between dendrimers and either synthetic or natural polymers, offering a combination of structural flexibility and functional performance. These systems enhance mechanical strength, allow for controlled drug release, and are capable of reacting to environmental factors like pH fluctuations or temperature shifts. As a result, they support sustained and precise delivery of therapeutic compounds, improving treatment precision.

4.3 Dendrimer–Metallic Nanoparticle Hybrids:

The integration of metallic nanoparticles into dendrimer frameworks has enabled innovative theragnostic applications, harnessing the optical, magnetic, or thermal properties of metals like gold, silver, or iron oxide, while the dendrimer structure ensures stability and surface functionalization. Gold dendrimer hybrids are extensively used in photothermal therapy to convert light into heat for selective cancer cell destruction, whereas iron oxide–dendrimer hybrids show great potential for MRI-guided drug delivery¹¹.

4.4 Dendrimer Carbon-Based Nanomaterial Hybrids:

Dendrimers can combine with carbon-based materials like carbon nanotubes, graphene oxide, or fullerenes to create hybrids with high drug-loading efficiency and strong cellular penetration. The carbon components offer a large surface area and π–π stacking for effective drug retention, while dendrimers add biocompatibility and functional sites for tumor-targeting ligands. These systems show promise against multidrug-resistant cancers by enabling enhanced uptake and precise delivery.

4.5 Multifunctional Dendrimer Hybrids:

Multifunctional dendrimer hybrids combine materials like lipids, polymers, metals, and carbon-based nanostructures into one platform for drug delivery, imaging, targeting, and therapy monitoring. Designed to respond to tumor-specific stimuli such as acidic pH or enzymes, and external triggers like heat or light, they enable precise and efficient cancer treatment¹².

5. Advantages and Limitations of Dendrimer Hybrids:

Advantages of Dendrimer Hybrids:

1. Multifunctionality and Targeted Delivery:

Dendrimer hybrids are designed with a highly branched and well-defined molecular architecture that enables them to carry several therapeutic and diagnostic agents simultaneously. This includes drugs, imaging molecules, and tumor-targeting ligands. This unique multivalent capacity allows accurate delivery of drugs specifically to tumor cells while reducing unintended effects on non-target tissues, thereby minimizing harm to healthy cells.

2. Enhanced Cellular Uptake and Barrier Penetration:

Due to their nanoscale size and adaptable surface properties, dendrimer hybrids are highly efficient at traversing biological barriers that are typically hard for standard drugs to overcome. Their capability to move through compact tissues, such as tumor vasculature, and even penetrate the blood–brain barrier, makes them particularly suitable for targeting brain cancers as well as other cancers that are difficult to treat.

3. Improved Pharmacokinetic and Biodistribution Profiles:

When dendrimers are functionalized with polymers such as polyethylene glycol (PEG) or combined with lipid structures, they exhibit prolonged circulation in the bloodstream, reduced clearance by immune cells, and more controlled drug release. These characteristics contribute to higher and more sustained drug concentrations at tumor sites, enhancing overall therapeutic outcomes¹³.

4. Synergistic Drug and Gene Co-Delivery:

A key advanced use of dendrimer hybrids lies in their capability to simultaneously deliver chemotherapeutic agents and genetic material (e.g., siRNA, plasmid DNA) within a unified system. This enables combination therapy approaches that target cancer through multiple mechanisms. For example, PEGylated dendrimer–lipid hybrids carrying paclitaxel alongside siRNA have shown significantly enhanced tumor reduction in laboratory studies compared to single-agent therapies.

Limitations of Dendrimer Hybrids:

1. Complex Synthesis and High Production Costs:

The creation and manufacturing of dendrimer hybrids frequently necessitate intricate chemical procedures that are not only time-intensive but also expensive and challenging to scale. The pursuit of uniformity and reproducibility in these complex structures continues to pose a significant obstacle, hindering their progression from research phases to commercial production.

2. Potential Toxicity from Surface Charge:

Cationic (positively charged) dendrimers have demonstrated the ability to disrupt cellular membranes, leading to adverse effects such as oxidative stress, hemolysis, or damage to mitochondria. While alterations to the surface can mitigate these toxic repercussions, safety issues remain a concern, especially at elevated dosages.

3. Limited Clinical Advancement:

Despite promising results in laboratory and animal studies, only a handful of dendrimer-based systems have advanced to human clinical trials. Regulatory uncertainties, the absence of long-term safety data, and the need for specialized characterization tools have contributed to the slow pace of clinical development¹⁴.

4. Challenges in Biodegradation and Excretion:

The mechanisms by which dendrimer hybrids are metabolized and expelled from the body are not yet completely understood. Some research indicates that they may build up in vital organs like the liver and kidneys, raising concerns regarding long-term biocompatibility. Ensuring thorough and safe elimination remains a critical area of ongoing investigation.

5. Regulatory and Scalability Hurdles:

Due to their novel and complex structure, dendrimer hybrids must pass extensive safety and efficacy evaluations before receiving regulatory approval. Additionally, scaling up production while maintaining consistent quality between batches is technically demanding, which makes commercialization a slow and challenging process¹⁵.

6. Recent Technological Advances in Dendrimer Hybrids :

1. Dendrimer–Lipid Hybrids:

One of the most exciting developments in the field involves the integration of dendrimers with lipid structures, including liposomes or lipid bilayers. This combination greatly enhances drug encapsulation, prolongs circulation time within the bloodstream, and minimizes toxicity. A significant advantage of these hybrids is their enhanced capability to penetrate the blood–brain barrier more effectively, making them suitable for managing brain cancers such as glioblastoma. The enhanced transport across physiological barriers paves the way for new possibilities in the therapy of central nervous system cancers.

2. Dendrimer–Polymer Hybrids:

Another important development is the grafting of polymers such as PEG, PLA, or chitosan onto dendrimers. These systems can react to specific factors in the tumor environment—like acidic conditions or enzyme activity—enabling precisely controlled release of therapeutic agents. This targeted approach reduces side effects and improves treatment specificity. Such hybrids are often designed to carry imaging probes or genetic material, functioning as multifunctional “theranostic” tools that allow ongoing tracking of disease and tailored cancer therapies.

3. Dendrimer–Metal Nanoparticle Hybrids:

Hybrids formed by integrating dendrimers with metal nanoparticles had shown immense potential for both imaging and therapy. These constructs can be used in techniques like MRI or photoacoustic imaging, while also enabling photothermal therapy (PTT). When exposed to stimuli like near-infrared light, the metal core generates localized heat, effectively killing tumor cells with minimal invasiveness. Some systems are also designed for responsive drug release triggered by conditions like high temperature or low pH in tumors, ensuring that treatment stays focused on the target site¹⁶.

4. Dendrimer–Carbon Nanostructure Hybrids:

Using carbon-based nanomaterials like graphene oxide or carbon nanotubes in combination with dendrimers enables efficient drug loading because of their extensive surface area. These systems can be tailored with targeting molecules—such as folic acid or antibodies—facilitating precise drug delivery to tumor sites.

5. Clinical Translation and Future Directions:

Although most dendrimer hybrid systems are still in preclinical stages, some—like PEGylated dendrimers and VivaGel—have entered clinical trials, showing promising safety and efficacy. Future generations are expected to feature dynamic, tumor-responsive designs, supporting the advancement of personalized and precision nanomedicine in oncology.

7. Clinical Translation and Future Directions of Dendrimer Hybrids:

A prominent illustration of clinical progress is VivaGel (SPL7013), initially developed for antiviral applications and later adapted for conditions such as bacterial vaginosis and sexually transmitted infections. The positive results from its clinical assessment highlight the safety and biocompatibility of PEGylated dendrimers in humans, reinforcing their potential as drug delivery systems in oncology. In preclinical oncology studies, dendrimer hybrids—especially those linked with lipids or metallic nanoparticles—have shown promising outcomes in animal models of aggressive cancers like glioblastoma, breast cancer, and colorectal cancer. These systems enable the simultaneous delivery of anticancer drugs, gene-based therapies, and diagnostic agents, thereby integrating treatment and diagnostics while minimizing systemic toxicity.

Despite these advancements, regulatory approval remains a considerable challenge, as organizations such as the U.S. FDA and EMA have not yet established specific guidelines for dendrimer hybrids, leading to their classification under broader nanomedicine regulations. Key obstacles include the lack of standardized protocols, limited long-term human safety data, and unclear policies for multi-component nanostructures. On the industrial front, pharmaceutical companies are increasingly investing in dendrimer hybrid platforms to target treatment-resistant and poorly responsive tumors, but complex synthesis, batch variability, and scalability issues continue to restrict widespread use¹⁷.

8. CONCLUSION:

Dendrimer hybrids have emerged as a powerful advancement in nanomedicine, offering precise drug delivery, enhanced bioavailability, and reduced toxicity—especially in the realm of cancer treatment. Their highly branched structure allows for the attachment or encapsulation of multiple therapeutic and diagnostic agents, enabling multimodal treatment strategies. By integrating with other nanomaterials such as liposomes, carbon nanotubes, gold nanoparticles, and magnetic particles, these systems enhance functionalities like targeted delivery, controlled drug release, and real-time imaging. This has opened the door for combination therapies, including chemotherapy with photothermal or gene therapies, and theranostic platforms that unify treatment and diagnostics within a single nanoscale construct. Future efforts are now focused on the development of intelligent, stimuli-responsive dendrimer hybrids capable of adapting to the dynamic tumor microenvironment. Innovations such as pH-triggered release, redox-sensitive behavior, immune evasion coatings, and AI-assisted design are expected to enhance therapeutic precision and patient safety. With sustained interdisciplinary collaboration across materials science, oncology, pharmacology, and bioengineering, dendrimer hybrids hold the promise to transform the landscape of personalized and targeted cancer treatments¹⁸.

9. REFERENCE:

1. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2005; 57(15): 2106–29.

2. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005; 10(1): 35–43.

3. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. 2014; 39(2): 268–307.

4. Chauhan AS. Dendrimers for drug delivery. Molecules. 2018; 23(4): 938.

5. Kannan RM, Nance E, Kannan S, Tomalia DA. Emerging concepts in dendrimer-based nanomedicine. J Intern Med. 2014; 276(6): 579–617.

6. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let’s meet the challenge. Int J Pharm. 2010; 394(1–2): 122–42.

7. Bai S, Thomas C, Rawat A. Dendrimer–lipid nanohybrids for anticancer drug delivery. Nanomedicine. 2019; 20:101986.

8. Huang D, Zhou H, Liu Y, Xu P. Dendrimer-based nanohybrids for cancer theranostics. Mater Today Bio. 2021; 10: 100109.

9. Tripathy S, Das MK, Das S. Dendrimer-based hybrid nanocarriers: Recent advances in cancer therapy. Artif Cells Nanomed Biotechnol. 2020; 48(1): 118.

10. Parveen S, Sahoo SK. Dendrimer–polymer hybrid nanostructures for cancer therapy. Expert Opin Drug Deliv. 2011; 8(7): 839–56.

11. Kesharwani P, Gupta U. Dendrimer–metal nanoparticle conjugates for cancer therapy. J Control Release. 2021; 330: 620–38.

12. Wang J, Liu X, Jin X. Dendrimer–carbon nanostructure hybrids in drug delivery and imaging. J Nanobiotechnology. 2020;18(1):130.

13. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Nanoparticle-based delivery of cancer drugs. Annu Rev Biomed Eng. 2012; 14: 185–210.

14. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv. 2007; 4(4): 297–305.

15. Tyagi N, Dhanjal JK, Mehta M. Dendrimer-based therapeutic systems. Int J Pharm. 2022; 617: 121564.

16. Boyd BJ, Porter CJH. VivaGel®: Clinical translation of dendrimer-based antivirals. Expert Opin Drug Deliv. 2019; 16(5): 493–503.

17. Mukherjee S. AI-assisted nanomedicine formulation: Personalized therapy. Comput Struct Biotechnol J. 2023; 21: 530–42.

18. Singh D, Singh M. Tumor microenvironment-responsive dendrimer systems. Front Pharmacol. 2022; 13: 856790.

19. Munro, N., Srinageshwar, B., Shalabi, F., Florendo, M., Otero, P., Thompson, C. A novel approach to label bone marrow-derived mesenchymal stem cells with mixed-surface PAMAM dendrimers. Stem Cell Research and Therapy. 2019; 10(1): 71.

20. Cleveland Clinic. Glioblastoma (GBM): What It Is, Symptoms & Prognosis. Cleveland Clinic Health Library. Last reviewed: April 23, 2025. Available from: https://my.clevelandclinic.org/health/diseases/17032-glioblastoma.

Received on 12.08.2025 Revised on 05.11.2025

Accepted on 10.01.2026 Published on 06.07.2026

Available online from July 20, 2026

Asian J. Pharm. Res. 2026; 16(3):289-294.

DOI: 10.52711/2231-5691.2026.00043

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.